Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Interest & Investment Income (2023 - 2026)

Unicycive Therapeutics filings provide 2 years of Interest & Investment Income readings, the most recent being $314000.0 for Q4 2024.

  • On a quarterly basis, Interest & Investment Income rose 124.29% to $314000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $1.3 million, a 105.04% increase, with the full-year FY2025 number at $1.0 million, down 19.75% from a year prior.
  • Interest & Investment Income hit $314000.0 in Q4 2024 for Unicycive Therapeutics, down from $416000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $462000.0 in Q2 2024 to a low of $14000.0 in Q1 2023.